Proton dynamics in cancer

Journal of Translational Medicine

Volumn 8, Issue , 2010, Pages

  Huber, Veronica ^a   De Milito, Angelo ^b,i   Harguindey, Salvador ^c   Reshkin, Stephan J ^d   Wahl, Miriam L ^e   Rauch, Cyril ^f   Chiesi, Antonio ^b   Pouysségur, Jacques ^g   Gatenby, Robert A ^h   Rivoltini, Licia ^a   Fais, Stefano ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c Institute of Clinical Biology and Metabolism   (Spain)

^d UNIVERSITY OF BARI   (Italy)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^g CNRS   (France)

^h H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

ⁱ KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

LACTIC ACID; PROTON PUMP INHIBITOR; GLUCOSE; PROTON; PROTON PUMP;

ANTINEOPLASTIC ACTIVITY; CANCER GROWTH; CARCINOGENESIS; CELL METABOLISM; CELL PROLIFERATION; CELL SURVIVAL; CHEMOSENSITIZATION; CLINICAL TRIAL; CYTOLOGY; DETOXIFICATION; GLYCOLYSIS; HUMAN; MELANOMA; MOLECULAR DYNAMICS; NEOPLASM; NOTE; OSTEOSARCOMA; PEPTIC ULCER; PROTON TRANSPORT; TUMOR CELL; TUMOR MICROENVIRONMENT; ANIMAL; EDITORIAL; METABOLISM; PATHOLOGY; PH; SCINTISCANNING;

ANIMALS; GLUCOSE; HUMANS; HYDROGEN-ION CONCENTRATION; NEOPLASMS; PROTON PUMPS; PROTONS;

EID: 77953373415     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-8-57     Document Type: Note

References (31)

1. Nygren P, Larsson R. Overview of the clinical efficacy of investigational anticancer drugs. J Intern Med 2003, 253:46-75. 10.1046/j.1365-2796.2003.01098.x, 12588538.
2. Gatenby RA. A change of strategy in the war on cancer. Nature 2009, 459:508-509. 10.1038/459508a, 19478766.
3. Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond. Cell 2008, 134:703-707. 10.1016/j.cell.2008.08.021, 18775299.
4. Pouyssegur J, Dayan F, Mazure N. Hypoxia signaling in cancer and approaches to enforce tumor regression. Nature 2006, 441:437-443. 10.1038/nature04871, 16724055.
5. Jin S, DiPaola RS, Mathew R, White E. Metabolic catastrophe as a means to cancer cell death. J Cell Sci 2007, 120:379-383. 10.1242/jcs.03349, 2857576, 17251378.
6. Tennant DA, Duran RV, Gottlieb E. Targeting metabolic transformation for cancer therapy. Nat Rev Cancer 2010, 10:267-277. 10.1038/nrc2817, 20300106.
7. Fais S, De Milito A, You H, Qin W. Targeting vacuolar H+-ATPases as a new strategy against cancer. Cancer Res 2007, 67:10627-10630. 10.1158/0008-5472.CAN-07-1805, 18006801.
8. Cardone RA, Casavola V, Reshkin SJ. The role of disturbed pH dynamics and the Na+/H+ exchanger in metastasis. Nat Rev Cancer 2005, 5:786-795. 10.1038/nrc1713, 16175178.
9. Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008, 7:168-181. 10.1038/nrd2467, 18167490.
10. Kenan DJ, Wahl ML. Ectopic localization of mitochondrial ATP synthase: a target for anti-angiogenesis intervention?. J Bioenerg Biomembr 2005, 37:461-465. 10.1007/s10863-005-9492-x, 16691484.
11. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009, 9:162-174. 10.1038/nri2506, 2828349, 19197294.
12. Martinez-Zaguilan R, Seftor EA, Seftor RE, Chu YW, Gillies RJ, Hendrix MJ. Acidic pH enhances the invasive behavior of human melanoma cells. Clin Exp Metastasis 1996, 14:176-186. 10.1007/BF00121214, 8605731.
13. Gatenby RA, Gillies RJ. A microenvironmental model of carcinogenesis. Nat Rev Cancer 2008, 8:56-61. 10.1038/nrc2255, 18059462.
14. Raghunand N, Martinez-Zaguilan R, Wright SH, Gillies RJ. pH and drug resistance. II. Turnover of acidic vesicles and resistance to weakly basic chemotherapeutic drugs. Biochem Pharmacol 1999, 57:1047-1058. 10.1016/S0006-2952(99)00021-0, 10796075.
15. Parolini I, Federici C, Raggi C, Lugini L, Palleschi S, De Milito A, Coscia C, Iessi E, Logozzi M, Molinari A, Colone M, Tatti M, Sargiacomo M, Fais S. Microenvironmental pH is a key factor for exosome traffic in tumor cells. J Biol Chem 2009, 284:34211-34222. 10.1074/jbc.M109.041152, 19801663.
16. Iero M, Valenti R, Huber V, Filipazzi P, Parmiani G, Fais S, Rivoltini L. Tumour-released exosomes and their implications in cancer immunity. Cell Death Differ 2008, 15:80-88. 10.1038/sj.cdd.4402237, 17932500.
17. Al-Nedawi K, Meehan B, Rak J. Microvesicles: messengers and mediators of tumor progression. Cell Cycle 2009, 8:2014-2018.
18. Lu X, Qin W, Li J, Tan N, Pan D, Zhang H, Xie L, Yao G, Shu H, Yao M, Wan D, Gu J, Yang S. The growth and metastasis of human hepatocellular carcinoma xenografts are inhibited by small interfering RNA targeting to the subunit ATP6L of proton pump. Cancer Res 2005, 65:6843-6849. 10.1158/0008-5472.CAN-04-3822, 16061667.
19. Lugini L, Matarrese P, Tinari A, Lozupone F, Federici C, Iessi E, Gentile M, Luciani F, Parmiani G, Rivoltini L, Malorni W, Fais S. Cannibalism of live lymphocytes by human metastatic but not primary melanoma cells. Cancer Res 2006, 66:3629-3638. 10.1158/0008-5472.CAN-05-3204, 16585188.
20. Rauch C. Toward a mechanical control of drug delivery. On the relationship between Lipinski's 2nd rule and cytosolic pH changes in doxorubicin resistance levels in cancer cells: a comparison to published data. Eur Biophys J 2009, 38:829-846. 10.1007/s00249-009-0429-x, 19296096.
21. Rauch C. On the relationship between drug's size, cell membrane mechanical properties and high levels of multi drug resistance: a comparison to published data. Eur Biophys J 2009, 38:537-546. 10.1007/s00249-008-0385-x, 19066880.
22. Rauch C, Pluen A. Multi drug resistance-dependent "vacuum cleaner" functionality potentially driven by the interactions between endocytosis, drug size and Pgp-like transporters surface density. Eur Biophys J 2007, 36:121-131. 10.1007/s00249-006-0113-3, 17211622.
23. Panagiotopoulou V, Richardson G, Jensen OE, Rauch C. On a biophysical and mathematical model of Pgp-mediated multidrug resistance: understanding the "space-time" dimension of MDR. Eur Biophys J 2010, 39:201-211. 10.1007/s00249-009-0555-5, 19888571.
24. Lozupone F, Perdicchio M, Brambilla D, Borghi M, Meschini S, Barca S, Marino ML, Logozzi M, Federici C, Iessi E, de Milito A, Fais S. The human homologue of Dictyostelium discoideum phg1A is expressed by human metastatic melanoma cells. EMBO Rep 2009, 10:1348-1354. 10.1038/embor.2009.236, 19893578.
25. Wahl ML, Owen JA, Burd R, Herlands RA, Nogami SS, Rodeck U, Berd D, Leeper DB, Owen CS. Regulation of intracellular pH in human melanoma: potential therapeutic implications. Mol Cancer Ther 2002, 1:617-628.
26. Harguindey S, Arranz JL, Wahl ML, Orive G, Reshkin SJ. Proton transport inhibitors as potentially selective anticancer drugs. Anticancer Res 2009, 29:2127-2136.
27. Chiche J, Ilc K, Laferriére J, Trottier E, Dayan F, Mazure NM, Brahimi-Horn MC, Pouysségur J. Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. Cancer Res 2009, 69:358-368. 10.1158/0008-5472.CAN-08-2470, 19118021.
28. De Milito A, Canese R, Marino ML, Borghi M, Iero M, Villa A, Venturi G, Lozupone F, Iessi E, Logozzi M, Della Mina P, Santinami M, Rodolfo M, Podo F, Rivoltini L, Fais S. pH-dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity. Int J Cancer 2010, 127:207-219.
29. De Milito A, Fais S. Tumor Acidity, Chemoresistance and Proton Pump Inhibitors. Future Oncology 2005, 1:779-786. 10.2217/14796694.1.6.779, 16556057.
30. Izumi H, Torigoe T, Ishiguchi H, Uramoto H, Yoshida Y, Tanabe M, Ise T, Murakami T, Yoshida T, Nomoto M, Kohno K. Cellular pH regulators: potentially promising molecular targets for cancer chemotherapy. Cancer Treat Rev 2003, 29:541-549. 10.1016/S0305-7372(03)00106-3, 14585264.
31. Harguindey S, Orive G, Luis Pedraz J, Paradiso A, Reshkin SJ. The role of pH dynamics and the Na+/H+ antiporter in the etiopathogenesis and treatment of cancer. Two faces of the same coin-one single nature. Bioch Biopyhs Acta 2005, 1756:1-24.